Opportunities and Obstacles Associated With Sequential Immune Reconstitution Therapy for Multiple Sclerosis: A Case Reportarticle Published on 2021-12-082024-09-02 Journal: Frontiers in Neurology [Category] 대상포진, [키워드] Alemtuzumab Case report Cladribine immune reconstitution therapy multiple sclerosis [DOI] 10.3389/fneur.2021.664596 PMC 바로가기 [Article Type] article
SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature다발성 경화증 환자에서 alemtuzumab 후 SARS-CoV-2 감염: 동시 감염 친척에 비해 가벼운 질병 증상: 증례 보고 및 문헌 검토Review Published on 2021-12-012022-09-12 Journal: Neurological Sciences [Category] MERS, SARS, 진단, [키워드] Alemtuzumab Anti-S1 benefit Case report Cladribine Complication coronavirus COVID-19 pandemic disease symptom drug female had no iatrogenic immunodeficiency Immunodepleting agents Infection literature lymphopenic mother Multiple multiple sclerosis Patient patients treated positive reported risk SARS-CoV-2 SARS-CoV-2 antibodies SARS-COV-2 infection SARS-CoV-2 virus severe complication severe disease significantly Symptom tested treated Treatment [DOI] 10.1007/s10072-021-05567-7 PMC 바로가기 [Article Type] Review
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis다발성 경화증에서 COVID-19 중증도와 질병 수정 요법의 연관성41 Published on 2021-11-092022-09-12 Journal: Neurology [Category] MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval Acetate adjusted adjusted odds ratio Admission admitted to ICU age Alemtuzumab analyzed artificial ventilation association Characteristics Cladribine Cohort coronavirus disease Coronavirus disease 2019 country covariate covariates COVID-19 COVID-19 cases COVID-19 severity cross-sectional design death demographic demonstrated died dimethyl fumarate disability EDSS EDSS score examined fumarate Glatiramer Glatiramer acetate higher risk Hospitalization Hospitalized ICU ICU admission immunosuppressive include increased risk indication intensive care intensive care unit interferon internal and external International Logistic regression Multiple multiple sclerosis Natalizumab objective Ocrelizumab Older age outcome outcomes Patient phenotype reflected required restriction Result risk factor rituximab scale sclerosis severe coronavirus disease severe COVID-19 severity Sex Siponimod status Stratification therapy Ventilation were assessed with COVID-19 [DOI] 10.1212/WNL.0000000000012753 PMC 바로가기 [Article Type] 41
Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patientsarticle Published on 2021-07-132024-09-02 Journal: Journal of Neurology [Category] 대상포진, [키워드] Alemtuzumab Autoimmunity drug-related side effects and adverse reactions incidence multiple sclerosis Safety [DOI] 10.1007/s00415-021-10664-w PMC 바로가기 [Article Type] article
Alemtuzumab in Covid era코로나 시대의 알렘투주맙Case Reports Published on 2021-06-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, [키워드] administration Alemtuzumab antibodies article clinician concerning Course COVID-19 COVID-19 infection disease evaluate fatality General population immunosuppressive drug Immunosuppressive treatment Infection MONITOR monoclonal antibody Multiple multiple sclerosis observation occurred pandemic era Patient patients patients treated physician Research risk risk of infection SARS-CoV-2 pandemic sclerosis screened serious COVID-19 subsequent therapy treated Treatment [DOI] 10.1016/j.msard.2021.102908 PMC 바로가기 [Article Type] Case Reports
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting TherapiesReview Published on 2021-01-282022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] acute respiratory syndrome Alemtuzumab antibody CD20 depletion Cladribine coronavirus coronavirus disease COVID COVID-19 disease-modifying drugs hazard immune-depleting therapies immunological effect in sight Multiple multiple sclerosis overcome pandemic question raised recommendation SARS-CoV-2 sclerosis therapy Treatment vaccination [DOI] 10.3390/vaccines9020099 PMC 바로가기 [Article Type] Review
COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID알렘투주맙으로 치료받은 다발성 경화증(MS) 환자의 COVID-19: COVID 이후의 면역 반응에 대한 통찰력Case Reports Published on 2020-11-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, [키워드] Activation acute respiratory syndrome Alemtuzumab Antigen antiviral response CD52 clinical evidence Comorbidity Complete coronavirus Coronavirus 2019 COVID COVID-19 deplete develop disease Hospitalization Hypothesis IgG immune response Immunity immunosuppressant agent immunosuppressed patient insight lymphocyte Mild monoclonal antibody monocyte Multiple multiple sclerosis Patient patient symptom Potential treatment Reinfection remittent risk SARS-CoV-2 Spread T cell T cell depletion T cells tested the disease Thompson treated [DOI] 10.1016/j.msard.2020.102447 PMC 바로가기 [Article Type] Case Reports
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumabCase Reports Published on 2020-10-012023-07-06 Journal: Multiple sclerosis and related disorders [Category] SARS, [키워드] Alemtuzumab COVID-19 Immunosuppression multiple sclerosis SARS-CoV-2 [DOI] 10.1016/j.msard.2020.102402 PMC 바로가기 [Article Type] Case Reports
Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab알렘투주맙으로 치료받은 중증 다발성 경화증 환자의 잠재적인 COVID-19 감염Article Published on 2020-09-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] 진단, [키워드] Administered age Alemtuzumab asked case sery changes in Clinical course COVID-19 COVID-19 infection COVID-19 pandemic Cytokine storm Defense Diagnosis Disease diagnosis dose EDSS evaluate females Frequency Hospital admission immune immune system immunosuppressive induce lymphocyte Lymphocyte count Mild symptom Multiple multiple sclerosis Patient patients treated positive Potential preliminary findings questionnaire receiving required Research SARS-CoV2 sclerosis severity of COVID-19 statistically significant difference Symptom symptoms of COVID-19 therapy treated Treatment Two patient with COVID-19 [DOI] 10.1016/j.msard.2020.102297 PMC 바로가기 [Article Type] Article
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension studyOriginal Research Papers Published on 2018-10-052024-09-04 Journal: Multiple Sclerosis Journal [Category] 대상포진, [키워드] Alemtuzumab Disease-modifying therapy Infection Relapsing-Remitting Multiple Sclerosis Safety [DOI] 10.1177/1352458518796675 PMC 바로가기 [Article Type] Original Research Papers